Rescission of NC State Health Director’s Standing Order Authorizing Subcutaneous Administration of Casirivimab/Imdevimab (REGEN-COV) Monoclonal Antibodies

I hereby rescind the standing order authorizing Subcutaneous Administration of Casirivimab/Imdevimab (REGEN-COV) Monoclonal Antibodies that was issued on January 5th, 2022 due to the high prevalence of the Omicron variant of SARS-CoV-2 virus in North Carolina for which REGEN-COV is not an effective treatment.

The rescission of this standing order shall not impact any actions taken in reliance on this standing order prior to the date of rescission.

Approved by: ____________________________  Date Signed: _1-24-22________________________

Elizabeth Cuervo Tilson, MD, MPH
NPI: 1760540421